It's always been.

Pharma companies will use Relative Risk Reduction when describing efficacy.

However, to truly understand the real benefits you must use Absolute Risk Reduction (or Number Needed to Treat is also a quality metric).

I haven't read the Lancet article linked to but I guarantee that's what's been done here.

It's always been.

Pharma companies will use Relative Risk Reduction when describing efficacy.

However, to truly understand the real benefits you must use Absolute Risk Reduction.

I haven't read the Lancet article linked to but I guarantee that's what's been done here.